Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Related Keywords

San Antonio ,Texas ,United States ,Germany ,German ,West German ,Oleg Gluz ,German Study Group ,Antonio Breast Cancer ,West German Study Group ,Adaptcycle Trial ,Nct04055493 ,The Addition Of Ovarian Function Suppression To Endocrine Therapy ,Patients With Hormone Receptor Positive ,Er2 Negative Early Breast Cancer ,D ,